• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
XVIVO
  • Contact us
  • Customer support
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
  • Corporate
  • The share
    • Info
    • Ownership structure
    • Insiders (PDMRs)
  • Press releases
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • Financial calendar
  • Financial reports
  • Financial reports – ESEF
  • Prospectus and material offerings
    • Material offerings
    • Prospectus
  • Financial presentations
    • Capital Markets Day
    • Earnings calls
  • Corporate governance
    • Article of Association
    • General meetings
    • Board of Directors
    • Senior Management
    • Auditors
    • Board Committees
    • Board and Senior Management share holdings
    • Guidelines for remuneration
    • Nomination Committee
    • Corporate Governance Reports
  • Analyst Coverage
  • Code of Conduct
  • Environmental Policy
  • Code of Conduct for Suppliers
  • Privacy policy
  • Contact us
  • Subscribe
  • Thank you
  • Error

Förändring av antalet aktier och röster i XVIVO Perfusion

Till följd av utnyttjande av teckningsoptioner har antalet aktier och röster i XVIVO Perfusion AB (publ) under juni 2018 ökat med 212 000 aktier och röster. Per den 29 juni 2018 finns därmed sammanlagt 26 402 496 aktier och röster i bolaget.

Göteborg 29 juni 2018
Christoffer Rosenblad, CFO
 
XVIVO Perfusion AB (publ)

För ytterligare information, vänligen kontakta:

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, VD, +46 31-788 21 50, magnus.nilsson@xvivoperfusion.com

För ytterligare information om XVIVO Perfusions verksamhet hänvisas till bolagets hemsida, www.xvivoperfusion.com

Denna information är sådan information som XVIVO Perfusion AB (publ) är skyldigt att offentliggöra enligt lagen om handel med finansiella instrument. Informationen lämnades för offentliggörande klockan 8.30 den 29 juni 2018.

About us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives.
Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on three continents. The company is listed on Nasdaq.

Contact

Swedish Office
XVIVO Perfusion AB
Box 53015
SE-400 14 Göteborg
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivogroup.com

 

Report a violations or breach here: Whistleblower

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2023 XVIVO. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO. Read more about Cookies

Approve